Post-Conference Perspectives: Managing R/R B-ALL with CAR T-Cell Therapy - Episode 4
R/R B-ALL: Key Safety Outcomes From the Updated Analysis of the ZUMA-3 Trial
Dr Jae Park discusses managing cytokine release syndrome and the neurotoxicity side effects of CAR T-cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia through medications, disease burden reduction, and earlier intervention to prevent severe toxicities.
